Dr. Purmal joined Cleveland BioLabs in 2005. He has spent over 15 years in small molecule drug development. He has a broad background in the chemistry of small molecules and biopolymers, analytical development, hit-to-lead optimization and preclinical drug development. As Chief Operating Officer of Incuron, LLC, Dr. Purmal oversees pre-clinical development related to CBLC137, a novel anti-cancer agent under development in the US and Russian Federation. Prior to joining CBLI Dr. Purmal was Vice President of Biochemical Research at V.I. Technologies, where he led a team of scientists developing a chemical process for inactivation of pathogens in human blood products for transfusions. Before this, Dr. Purmal worked as a Principal Scientist at Pentose Pharmaceuticals, where he led a team that identified a novel, small molecule DNA-targeted agent for broad spectrum pathogen inactivation. The success of Dr. Purmal’s research team led to Pentose being acquired by V.I. Technologies, Inc., which continued to sponsor clinical studies of this program. Prior to 1997, Dr. Purmal held several senior research academic positions at the University of Vermont, University of Illinois and Moscow State University. Dr. Purmal holds a Ph.D. degree in Chemistry from Moscow State University.

  small molecule DNA-targeted